中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肠道微生态与肝性脑病的关系

黄云义 刘尧 张群 时克 王宪波

引用本文:
Citation:

肠道微生态与肝性脑病的关系

DOI: 10.3969/j.issn.1001-5256.2020.04.045
基金项目: 

首都卫生发展科研专项(首发2018-1-2172); 北京市医院管理局临床医学发展专项经费资助(ZYLX201707); 北京市科学技术委员会资助(Z191100006619033); 

详细信息
  • 中图分类号: R575.3

Association of intestinal microecology with hepatic encephalopathy

Research funding: 

 

  • 摘要: 肝性脑病(HE)是肝硬化患者常见的一种复杂的神经精神性并发症,具有高发病率、高复发率及高病死率的特点,也是住院和再住院风险增加的一个重要因素。目前对于HE的治疗尚无特效药物,近年来研究发现,肠道微生态变化与HE的发生、发展及预后相关,而且调整肠道菌群对HE有一定的预防性作用。旨在对近年来肠道微生态与HE之间关系的研究进行总结,希望为临床防治HE提供新的治疗思路。

     

  • [1] WU ZW,LI LJ. Liver cirrhosis bacterial infection and intestinal bacterial flora[J]. J Mod Med Health,2019,35(2):161-163.(in Chinese)吴仲文,李兰娟.肝硬化细菌感染与肠道菌群[J].现代医药卫生,2019,35(2):161-163.
    [2] PRASAD S,DHIMAN RK,DUSEJA A,et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy[J].Hepatology,2007,45(3):549-559.
    [3] OTHMAN M,AGUERO R,LIN HC. Alterations in intestinal microbial flora and human disease[J]. Curr Opin Gastroenterol,2008,24(1):6-11.
    [4] SHIMIZU K,OGURA H,GOTO M,et al. Altered gut flora and environment in patients with severe SIRS[J]. J Trauma,2006,60(1):126-133.
    [5] WONG F,BERNARDI M,BALK R,et al. Sepsis in cirrhosis:Report on the 7th meeting of the International Ascites Club[J].Gut,2005,54(5):718-725.
    [6] SHAWCROSS DL,WRIGHT G,OLDE DAMINK SWM,et al.Role of ammonia and inflammation in minimal hepatic encephalopathy[J]. Metab Brain Dis,2007,22(1):125-138.
    [7] HAUSSINGER D,SCHLIESS F. Pathogenetic mechanisms of hepatic encephalopathy[J]. Gut,2008,57(8):1156-1165.
    [8] SHAWCROSS DL,SHRIFI Y,CANAVAN JB,et al. Infection and systemic inflammation,not ammonia,are associated with Grade 3/4 hepatic encephalopathy,but not mortality in cirrhosis[J]. J Hepatol,2010,54(4):640-649.
    [9] WRIGHT G,JALAN R. Ammonia and inflammation in the pathogenesis of hepatic encephalopathy:Pandora’s box?[J].Hepatology,2007,46(2):291-294.
    [10] QIN N,YANG FL,LI A,et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature,2014,513(7516):59-64.
    [11] BAJAJ JS,HYLEMON PB,RIDLON JM,et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation[J]. Am J Physiol Gastrointest Liver Physiol,2012,303:g675-g685.
    [12] JASMOHAN S,BAJAJ JS. The role of microbiota in hepatic encephalopathy[J]. Gut Microbes,2014,5(3):397-403.
    [13] MONTGOMERY JY,BAJAJ JS. Advances in the evaluation and management of minimal hepatic encephalopathy[J]. Curr Gastroenterol Rep,2011,13(1):26-33.
    [14] MARIA S,ALITA M,CHPY V,et al. In-hospital mortality and economic burden associated with hepatic encephalopathy in the united states from 2005 to 2009[J]. Clin Gastroenterol Hepatol,2012,10(9):1034-1041.
    [15] RIORDAN SM,WILLIAMS R. Gut flora and hepatic encephalopathy in patients with cirrhosis[J]. N Engl J Med,2010,362(12):1140-1142.
    [16] SHAWCROSS DL,SHARIFI Y,CAVANAN JB,et al. Infection and systemic inflammation,not ammonia,are associated with Grade 3/4 hepatic encephalopathy,but not mortality in cirrhosis[J]. J Hepatol,2011,54(4):640-649.
    [17] BAJAJ JS,RIDLON JM,HYLEMON PB,et al. Linkage of gut microbiome with cognition in hepatic encephalopathy[J]. Am J Physiol Gastrointest Liver Physiol,2012,302(1):g168-g175.
    [18] ZHANG ZG,ZHAI HQ,GENG JW,et al. Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing[J]. Am J Gastroenterol,2013,108(10):1601-1611.
    [19] NOBLE NA,WHITE MB,MONTEITH P,et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation[J]. Am J Physiol,2012,303(3 Pt 1):g675-g685.
    [20] Chinese Society of Hepatology,Chinese Medical Association.Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol,2018,34(10):2076-2089.(in Chinese)中华医学会肝病学分会.肝硬化肝性脑病诊疗指南[J].临床肝胆病杂志,2018,34(10):2076-2089.
    [21] LOKESH J,BARJESH CS,PRAVEEN S,et al. Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy[J]. Dig Liver Dis,2012,44(12):1027-1031.
    [22] SHARMA BC,SHARMA P,AGRAWAL A,et al. Secondary prophylaxis of hepatic encephalopathy:An open-label randomized controlled trial of lactulose versus placebo[J]. Gastroenterology,2009,137(3):885-891.
    [23] BASS NM,MULLEN KD,SANYAL A,et al. Rifaximin treatment in hepatic encephalopathy[J]. N Engl J Med,2010,362(12):1071-1081.
    [24] TAKUMI K,FUMITAKA S,MASATOSHI I,et al. Rifaximin-altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy:An exploratory data analysis of phase II/III clinical trials[J]. Hepatol Res,2019,49(4):404-418.
    [25] BAJAJ JS,HEUMAN DM,HYLEMON PB,et al. Randomised clinical trial:Lactobacillus GG modulates gut microbiome,metabolome and endotoxemia in patients with cirrhosis[J]. Aliment Pharmacol Ther,2014,39(10):1113-1125.
    [26] MILLION M,MARANINCHI M,HENRY M,et al. Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii[J]. Int J Obes,2012,36(6):817-825.
    [27] ELSHAGHABEE-FOUAD MF,BOCKELMANN W,MESKE D,et al. Ethanol production by selected intestinal microorganisms and lactic acid bacteria growing under different nutritional conditions[J]. Front Microbiol,2016,7(7):1-13.
    [28] MARLICZ W,WUNSCH E,MYDLOWSKA M,et al. The effect of short term treatment with probiotic VSL#3 on various clinical and biochemical parameters in patients with liver cirrhosis[J].J Physiol Pharmacol,2016,67(6):867-877.
    [29] SAMMY S,DUMINDA S,JENNIFER A,et al. Probiotics are helpful in hepatic encephalopathy:A meta-analysis of randomized trials[J]. Liver Int,2016,36(7):986-993.
    [30] SHAVAKHI A,HASHEMI H,TABESH E,et al. Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy[J]. J Res Med Sci,2014,19(8):703-708.
    [31] KAPIL S,SANJAY P,SRIPHAKASH M,et al. Effect of rifaximin,probiotics,and l-ornithine l-aspartate on minimal hepatic encephalopathy:A randomized controlled trial[J]. Saudi J Gastroenterol,2014,20(4):225.
    [32] SHULIA S,MAHL TC,GUHA S. Letter:Probiotics vs. lactulose for minimal hepatic encephalopathy therapy—authors’reply[J]. Aliment pharmacol Ther,2014,39(9):1000.
    [33] VIRAMONTES HD,AVERY A,STOW R. The Effects of probiotics and symbiotics on risk factors for hepatic encephalopathy:A systematic review[J]. J Clin Gastroenterol,2017,51(4):312-323.
    [34] OWENS C,BROUSSARD E,SURAWICZ C. Fecal microbiota transplantation and donor standardization[J]. Trends Microbiol,2013,21(9):443-445.
    [35] BAJAJ JS,KASSAM Z,FAGAN A,et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy:A randomized clinical trial[J]. Hepatology,2017,66(6):1727-1738.
    [36] TANDON P,MADSEN K,KAO D. Fecal microbiota transplantation for hepatic encephalopathy:Ready for prime time?[J].Hepatology,2017,66(6):1713-1715.
    [37] JACOB V,CRAWFORD C,COHEN-MEKEBURG S,et al.Single delivery of high-diversity fecal microbiota preparation by colonoscopy is safe and effective in increasing microbial diversity in active ulcerative colitis[J]. Inflamm Bowel Dis,2017,23(6):903-911.
  • 加载中
计量
  • 文章访问数:  818
  • HTML全文浏览量:  43
  • PDF下载量:  272
  • 被引次数: 0
出版历程
  • 出版日期:  2020-04-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回